News | June 09, 2024
Gavi outlines plans to support access to new vaccines
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
Takes charge to lead business innovation, strategy, alliance & partnerships
Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine
The President said that there is a need to spread more and more awareness regarding the causes, diagnosis and treatment of cancer
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare
Subscribe To Our Newsletter & Stay Updated
